AD/PD 2021: A New Neuro-Regenerative Therapeutic Approach Targeting Protein Kinase C for the Treatment of Alzheimer’s Disease

At the 15th International Virtual Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) 2021, a clinical-stage biotech company based in New York, US Synaptogenix, presented its product bryostatin-1 for AD, a novel therapeutic designed to restore cognitive function and regenerate cerebral connections.